• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肠道微生物群作为心血管代谢紊乱的生物标志物。

Gut microbiome as a biomarker of cardiometabolic disorders.

作者信息

Gózd-Barszczewska Anna, Kozioł-Montewka Maria, Barszczewski Piotr, Młodzińska Agata, Humińska Kinga

机构信息

Division of Cardiology with Cardiac Intensive Care Unit, Cardinal Stefan Wyszyński Hospital, Lublin, Poland.

Pope John Paul II State School of Higher Education, Biała Podlaska, Poland.

出版信息

Ann Agric Environ Med. 2017 Sep 21;24(3):416-422. doi: 10.26444/aaem/75456. Epub 2017 Sep 8.

DOI:10.26444/aaem/75456
PMID:28954482
Abstract

INTRODUCTION AND OBJECTIVE

Cardiovascular diseases are the leading cause of death in Europe and worldwide. One of the most important risk factors for atherosclerosis are lipid metabolism disorders, in particular hipercholesterolaemia. The aim of the study was to determine the correlation between gut microbiota composition and atherosclerosis risk factors, so in order that it might be used as a biomarker for coronary artery disease diagnosis.

MATERIAL AND METHODS

The study involved middle-aged men in eastern Poland with central obesity (n=20), subjects with atherosclerosis (n=15) and those with no cardiovascular diseases (n=5). The gut microbiota composition was determined using tag-encoded 16S rRNA gene using Illuminal MiSeq. Data were analyzed with the use of t-test.

RESULTS

Firmicutes (49.26%) and Bacteroidetes (44.46%) were the dominant Phyla in the middle-aged men in eastern Poland. Subjects with improper levels of total cholesterol were enriched in Prevotella (p=0.03) and decreased level of Clostridium (p=0.02). They also showed a falling tendency in Faecalibacterium (p=0.07). An upward trend was observed in Prevotella (p=0.07) in subjects with improper LDL-C values.

CONCLUSIONS

The study showed that intestinal microbiome is likely to play a role in the pathogenesis of atherosclerosis through its role in lipid metabolism. Bacterial genera of particular importance were Prevotella, Bacteroides, Clostridium, Faecalibacterium. However, further studies involving larger groups of subjects are required to confirm these observations.

摘要

引言与目的

心血管疾病是欧洲乃至全球的主要死因。动脉粥样硬化最重要的危险因素之一是脂质代谢紊乱,尤其是高胆固醇血症。本研究的目的是确定肠道微生物群组成与动脉粥样硬化危险因素之间的相关性,以便将其用作冠状动脉疾病诊断的生物标志物。

材料与方法

该研究纳入了波兰东部患有中心性肥胖的中年男性(n = 20)、患有动脉粥样硬化的受试者(n = 15)以及无心血管疾病的受试者(n = 5)。使用Illuminal MiSeq通过标签编码的16S rRNA基因确定肠道微生物群组成。数据采用t检验进行分析。

结果

在波兰东部的中年男性中,厚壁菌门(49.26%)和拟杆菌门(44.46%)是主要的菌门。总胆固醇水平异常的受试者中普雷沃氏菌属增多(p = 0.03),梭菌属水平降低(p = 0.02)。他们的粪杆菌属也呈下降趋势(p = 0.07)。低密度脂蛋白胆固醇(LDL-C)值异常的受试者中普雷沃氏菌属呈上升趋势(p = 0.07)。

结论

该研究表明肠道微生物群可能通过其在脂质代谢中的作用在动脉粥样硬化的发病机制中发挥作用。特别重要的细菌属有普雷沃氏菌属、拟杆菌属、梭菌属、粪杆菌属。然而,需要进一步纳入更大样本量受试者的研究来证实这些观察结果。

相似文献

1
Gut microbiome as a biomarker of cardiometabolic disorders.肠道微生物群作为心血管代谢紊乱的生物标志物。
Ann Agric Environ Med. 2017 Sep 21;24(3):416-422. doi: 10.26444/aaem/75456. Epub 2017 Sep 8.
2
Enterotype May Drive the Dietary-Associated Cardiometabolic Risk Factors.肠型可能驱动与饮食相关的心血管代谢危险因素。
Front Cell Infect Microbiol. 2017 Feb 23;7:47. doi: 10.3389/fcimb.2017.00047. eCollection 2017.
3
Characteristics of gut microbiota in people with obesity.肥胖人群的肠道微生物特征。
PLoS One. 2021 Aug 10;16(8):e0255446. doi: 10.1371/journal.pone.0255446. eCollection 2021.
4
The gut microbiome and elevated cardiovascular risk in obesity and autoimmunity.肠道微生物组与肥胖和自身免疫中的心血管风险升高。
Atherosclerosis. 2018 Apr;271:203-213. doi: 10.1016/j.atherosclerosis.2018.02.036. Epub 2018 Mar 2.
5
The Gut Microbiome Contributes to a Substantial Proportion of the Variation in Blood Lipids.肠道微生物群在血脂变化中占相当大的比例。
Circ Res. 2015 Oct 9;117(9):817-24. doi: 10.1161/CIRCRESAHA.115.306807. Epub 2015 Sep 10.
6
Deciphering the Human Gut Microbiome of Urolithin Metabotypes: Association with Enterotypes and Potential Cardiometabolic Health Implications.解析尿石素代谢型的人类肠道微生物组:与肠型的关联及其对心血管代谢健康的潜在影响。
Mol Nutr Food Res. 2019 Feb;63(4):e1800958. doi: 10.1002/mnfr.201800958. Epub 2018 Dec 3.
7
Microbial Community of Healthy Thai Vegetarians and Non-Vegetarians, Their Core Gut Microbiota, and Pathogen Risk.健康泰国素食者和非素食者的微生物群落、其核心肠道微生物群以及病原体风险
J Microbiol Biotechnol. 2016 Oct 28;26(10):1723-1735. doi: 10.4014/jmb.1603.03057.
8
Gut Microbiota and Subclinical Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus.肠道微生物群与 2 型糖尿病患者的亚临床心血管疾病。
Nutrients. 2021 Aug 1;13(8):2679. doi: 10.3390/nu13082679.
9
[The relationship between gut microbiota and cardiovascular diseases].[肠道微生物群与心血管疾病之间的关系]
G Ital Cardiol (Rome). 2016 Jan;17(1):11-4. doi: 10.1714/2140.23182.
10
The Effect of Lean-Seafood and Non-Seafood Diets on Fecal Metabolites and Gut Microbiome: Results from a Randomized Crossover Intervention Study.低脂-海鲜和非海鲜饮食对粪便代谢产物和肠道微生物组的影响:一项随机交叉干预研究的结果。
Mol Nutr Food Res. 2019 Jan;63(1):e1700976. doi: 10.1002/mnfr.201700976. Epub 2018 Apr 16.

引用本文的文献

1
Role of gut microbiota and derived metabolites in cardiovascular diseases.肠道微生物群及其衍生代谢产物在心血管疾病中的作用。
iScience. 2025 Jul 30;28(9):113247. doi: 10.1016/j.isci.2025.113247. eCollection 2025 Sep 19.
2
Microbial Metabolites and Cardiovascular Dysfunction: A New Era of Diagnostics and Therapy.微生物代谢产物与心血管功能障碍:诊断与治疗的新时代。
Cells. 2025 Aug 11;14(16):1237. doi: 10.3390/cells14161237.
3
Disturbance of gut microbiota in diabetes related macroangiopathy: Evidence from the gut bacteriome and mycobiome.
糖尿病相关大血管病变中肠道微生物群的紊乱:来自肠道细菌组和真菌组的证据。
iScience. 2025 Jun 9;28(7):112856. doi: 10.1016/j.isci.2025.112856. eCollection 2025 Jul 18.
4
The association between the oral microbiome and hypertension: a systematic review.口腔微生物群与高血压之间的关联:一项系统评价。
J Oral Microbiol. 2025 Feb 2;17(1):2459919. doi: 10.1080/20002297.2025.2459919. eCollection 2025.
5
Gut bacteria: an etiological agent in human pathological conditions.肠道细菌:人类病理条件的病因。
Front Cell Infect Microbiol. 2024 Oct 8;14:1291148. doi: 10.3389/fcimb.2024.1291148. eCollection 2024.
6
Intestinal microbiome as a diagnostic marker of coronary artery disease: a systematic review and meta-analysis.肠道微生物群作为冠状动脉疾病的诊断标志物:一项系统评价和荟萃分析。
Ann Med Surg (Lond). 2024 Sep 4;86(10):6105-6120. doi: 10.1097/MS9.0000000000002516. eCollection 2024 Oct.
7
Impact of the gut microbiome on atherosclerosis.肠道微生物群对动脉粥样硬化的影响。
mLife. 2024 Apr 1;3(2):167-175. doi: 10.1002/mlf2.12110. eCollection 2024 Jun.
8
Probiotics combined with atorvastatin administration in the treatment of hyperlipidemia: A randomized, double-blind, placebo-controlled clinical trial.益生菌联合阿托伐他汀治疗高脂血症的随机、双盲、安慰剂对照临床试验。
Medicine (Baltimore). 2024 May 24;103(21):e37883. doi: 10.1097/MD.0000000000037883.
9
Advances in the study of the interaction between schistosome infections and the host's intestinal microorganisms.血吸虫感染与宿主肠道微生物相互作用研究进展。
Parasit Vectors. 2024 Apr 10;17(1):185. doi: 10.1186/s13071-024-06245-1.
10
The Gut Microbiome Affects Atherosclerosis by Regulating Reverse Cholesterol Transport.肠道微生物组通过调节胆固醇逆转运影响动脉粥样硬化。
J Cardiovasc Transl Res. 2024 Jun;17(3):624-637. doi: 10.1007/s12265-024-10480-3. Epub 2024 Jan 17.